Future of Biogen's Aduhelm hinges on U.S. Medicare Alzheimer's coverage
The future of Aduhelm, Biogen Inc's (BIIB.O) controversial and expensive Alzheimer's drug, may hinge on a decision due this week from the U.S. Medicare program on whether it will pay for the treatm...